01683nam 2200421 a 450 991070072350332120111011141730.0(CKB)5470000002411775(OCoLC)741958525(EXLCZ)99547000000241177520110721d2011 ua 0engurbn||||a||||txtrdacontentcrdamediacrrdacarrierStaff report on Sanofi's strategic use of third parties to influence the FDA[electronic resource] /prepared by the staff of the Committee on Finance, United States SenateWashington :U.S. G.P.O.,2011.1 online resource (iii, 177 pages)S. prt. ;112-20Title from title screen (viewed on July 21, 2011).At head of title: 112th Congress, 1st session. Committee print.Paper version available for sale by the Supt. of Docs., U.S. G.P.O."May 2011."Includes bibliographical references.Drug approvalCorrupt practicesUnited StatesAnticoagulants (Medicine)Government policyUnited StatesGeneric drugsGovernment policyUnited StatesDrug approvalCorrupt practicesAnticoagulants (Medicine)Government policyGeneric drugsGovernment policyUnited States.Congress.Senate.Committee on Finance.GPOGPOBOOK9910700723503321Staff report on Sanofi's strategic use of third parties to influence the FDA3197227UNINA